http://jneuroengrehab.biomedcentral.com/articles/10.1186/s12984-016-0135-8
- Yu-Ching Lin,
- I-Ling Lin,
- Te-Feng Arthur Chou and
- Hsin-Min LeeEmail author
Journal of NeuroEngineering and Rehabilitation201613:25
DOI: 10.1186/s12984-016-0135-8
© Lin et al. 2016
Received: 18 July 2015
Accepted: 7 March 2016
Published: 12 March 2016
Abstract
Background
Cerebral palsy (CP) is the
most common pediatric disease to cause motor disability. Two common
symptoms in CP are spasticity and contracture. If this occurred in the
ankle plantar flexors of children with CP, it will impair their gait and
active daily living profoundly. Most children with CP receive botulinum
toxin type A (BoNT-A) injection to reduce muscle tone, but a knowledge
gap exists in the understanding of changes of neural and non-neural
components of spasticity after injection. The purpose of this study was
to determine if our device for quantitative modified Tardieu approach
(QMTA) is a valid method to assess spasticity of calf muscles after
botulinum toxin injection.
Methods
In this study, we intended to
develop a device for quantitative measurement of spasticity in calf
muscles based on the modified Tardieu scale (MTS) and techniques of
biomedical engineering. Our QMTA measures the angular displacement and
resistance of stretched joint with a device that is light, portable and
can be operated similar to conventional approaches for MTS. The static
(R2), dynamic (R1) and R2-R1 angles derived from the reactive signals
collected by the miniature sensors are used to represent the non-neural
and neural components of stretched spastic muscles. Four children with
CP were recruited to assess the change in spasticity in their
gastrocnemius muscles before and 4 weeks after BoNT-A injection.
Results
A simulated ankle model
validated the performance of our device in measuring joint displacement
and estimating the angle of catch. Data from our participants with CP
showed that R2 and R2-R1 improved significantly after BoNT-A
administration. It indicates both neural and non-neural components of
the spastic gastrocnemius muscles improved at four weeks after BoNT-A
injection in children with CP.
Conclusion
Our device for QMTA can
objectively measure the changes in spasticity of the gastrocnemius
muscle in children with cerebral palsy after BoNT-A injection.
No comments:
Post a Comment